Vanda Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $56,258 | $52,590 | $50,041 | $53,185 |
Gross Profit | 53,304 | 48,103 | 46,520 | 50,595 |
EBITDA | -29,231 | -32,869 | -31,115 | -8,305 |
EBIT | -31,284 | -34,886 | -32,095 | -10,279 |
Net Income | -22,586 | -27,207 | -29,494 | -4,912 |
Net Change In Cash | 56,258 | 52,590 | 50,041 | 53,185 |
Free Cash Flow | -31,787 | -15,551 | -33,583 | -2,031 |
Cash | 70,022 | 80,983 | 111,796 | 102,316 |
Basic Shares | 58,873 | 58,993 | 58,527 | 58,308 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $198,772 | $192,640 | $254,382 | $268,682 |
Gross Profit | 187,458 | 192,640 | 230,100 | 243,053 |
EBITDA | -32,528 | -13,952 | 9,062 | 45,006 |
EBIT | -40,660 | -13,952 | 6,329 | 42,165 |
Net Income | -18,900 | 2,509 | 6,275 | 33,152 |
Net Change In Cash | 198,772 | 192,640 | 254,382 | 268,682 |
Cost of Revenue | 82,643 | -8,932 | ||
Free Cash Flow | -16,247 | 12,418 | 31,305 | 63,662 |
Cash | 102,316 | 135,821 | 135,029 | 52,071 |
Basic Shares | 58,149 | 57,557 | 56,983 | 56,921 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.38 |
2025-06-30 | -$0.46 |
2025-03-31 | -$0.50 |
2024-12-31 | -$0.08 |
